Cirrhosis/Liver Failure News

Magnetic resonance elastography appeared to accurately identify fibrosis in patients with homozygous Z genotype alpha-1 antitrypsin deficiency, according to a pilot prospective study published in Alimentary Pharmacology & Therapeutics.

In patients with acute liver failure, controlled moderate hypothermia could not limit the development of brain swelling as was suggested by previous studies, according to new data published in the Journal of Hepatology.

The clinical frailty scale — a 1-minute bedside screening test — appeared to better detect unplanned hospitalization or death in outpatients with cirrhosis, according to recent findings published in the American Journal of Gastroenterology.

In patients with hepatitis C, both atorvastatin and fluvastatin use were associated with a dose-dependent reduction in both cirrhosis and hepatocellular carcinoma, according to recent findings published in Hepatology.

Numerous developments were made in the field of hepatology this week, therefore Healio.com/Hepatology compiled a list of the most read research and news in hepatology presented during the week.

According to recent findings published in Hepatology, nonalcoholic fatty liver disease was the most common cause of cirrhosis in a cohort comprising whites, blacks, Latinos, Japanese Americans and Native Hawaiians.

A recent meta-analysis published in Hepatology reaffirmed the benefits of nonabsorbable disaccharides for treatment and prevention of both overt and minimal hepatic encephalopathy.

Urine neutrophil gelatinase-associated lipocalin was prevalent in patients with acute-on-chronic liver failure and correlated with prognosis, suggesting it was a successful biomarker for identifying this type of liver disease in patients with cirrhosis.

Researchers identified obesity and type 2 diabetes as risk factors for chronic liver disease — more so than excessive alcohol use — among a population of adults in the United Kingdom, according to data presented at the British Society of Gastroenterology Annual Meeting.

Administering testosterone to men with cirrhosis and low testosterone safely and effectively increased muscle and bone mass, suggesting testosterone may increase survival for this patient population, according to results of a placebo-controlled trial.